CHRISTOPHER JENNINGS

Advocate for policies designed to improve the long-term care delivery structure by providing home and community-based state options, addressing health care workforce shortages and ensuring quality in care delivery as well as health reform initiatives to ensure adequacy of subsidies/tax credits to achieve affordable coverage for the under 65 population (including but not limited to HR 3200, HR 3495).

Advocate for policies designed to improve the long-term care delivery structure by providing home and community-based state options, addressing health care workforce shortages and ensuring quality in care delivery as well as health reform initiatives to ensure adequacy of subsidies/tax credits to achieve affordable coverage for the under 65 population (including but not limited to HR 3200, HR 3495).

Advocate for cost containment policies, including generic access and the removal of barriers to greater competition in the pharmaceutical marketplace (including but not limited to H.R. 1427, S. 726, HR 3200, HR 3495 and H.R. 1548).

Advocate for cost containment policies, including generic access and the removal of barriers to greater competition in the pharmaceutical marketplace (including but not limited to H.R. 1427, S. 726, HR 3200, HR 3495 and H.R. 1548).

Advocate for policies designed to ensure quality in care delivery as well as health reform initiatives to ensure adequacy of subsidies/tax credits to achieve affordable coverage for the under 65 population (including but not limited to HR 3200).

Monitor health reform legislation, provided strategic advice on issues related to pending health reform legislation including physician quality reporting requirements and palliative care.

Monitor health reform legislation, provided strategic advice on issues related to pending health reform legislation including physician quality reporting requirements and palliative care.

Provide background information regarding the political and policy status of health care reform, including the development and structuring of health reform initiatives and how they could impact the hospital sector (including but not limited to HR 3200).

Provide background information regarding the political and policy status of health care reform, including the development and structuring of health reform initiatives and how they could impact the hospital sector (including but not limited to HR 3200).

Advocate for policies related to the development of public standards for food ingredients and safety (including but not limited to S. 3385).

Advocate for policies related to the development of public standards for food ingredients and safety (including but not limited to S. 3385).

Advocate for cost containment initiatives such as comparative effectiveness research and patient safety (including but not limited to S. 3408); advocate for policies related to the development and utilization of a state and/or federal prescription drug formulary (including, but not limited to, HR 3200).

Advocate for initiatives designed to improve safety, enhance quality and constrain costs through generic utilization and pharmacy management techniques, as well as promote initiatives aimed at developing a policy to provide home delivery and counseling services for the chronically ill population; advocate for the creation of a workable, science-based regulatory pathway for access to affordable generic biologic medications a (including but not limited to H.R. 1427, S. 726, H.R. 1548).

Advocate for initiatives designed to improve safety, enhance quality and constrain costs through generic utilization and pharmacy management techniques, as well as promote initiatives aimed at developing a policy to provide home delivery and counseling services for the chronically ill population; advocate for the creation of a workable, science-based regulatory pathway for access to affordable generic biologic medications a (including but not limited to H.R. 1427, S. 726, H.R. 1548).

Advocate for biopharmaceutical cost containment policies aimed at creating a workable, science-based regulatory pathway for access to affordable generic biologic medications (including but not limited to H.R. 1427, S. 726 and H.R. 1548)

Advocate for biopharmaceutical cost containment policies aimed at creating a workable, science-based regulatory pathway for access to affordable generic biologic medications (including but not limited to H.R. 1427, S. 726 and H.R. 1548)

Advocate for the creation of a regulatory pathway for generic biologic medications and policies that promotes innovation and competition and ensures affordability in the pharmaceutical marketplace, including but not limited to H.R. 1427, S. 726 and H.R. 1548).

Advocate for the creation of a regulatory pathway for generic biologic medications and policies that promotes innovation and competition and ensures affordability in the pharmaceutical marketplace, including but not limited to H.R. 1427, S. 726 and H.R. 1548).

Advocate for policies designed to improve the long-term care delivery structure by providing home and community-based state options, addressing health care workforce shortages and ensuring quality in care delivery as well as health reform initiatives to ensure adequacy of subsidies/tax credits to achieve affordable coverage for the under 65 population.

Advocate for policies designed to improve the long-term care delivery structure by providing home and community-based state options, addressing health care workforce shortages and ensuring quality in care delivery as well as health reform initiatives to ensure adequacy of subsidies/tax credits to achieve affordable coverage for the under 65 population.

Advocate for cost containment policies, including generic access and the removal of barriers to greater competition in the pharmaceutical marketplace (including but not limited to H.R. 1427, S. 726 and H.R. 1548).

Advocate for cost containment policies, including generic access and the removal of barriers to greater competition in the pharmaceutical marketplace (including but not limited to H.R. 1427, S. 726 and H.R. 1548).

Average Manufacturers Price/AMP including H.R. 6331 Any matters relating to access to generic drugs

Monitor health reform legislation, provided strategic advice on issues related to pending health reform legislation including physician quality reporting requirements and palliative care.

Monitor health reform legislation, provided strategic advice on issues related to pending health reform legislation including physician quality reporting requirements and palliative care.

Advocate for policies designed to ensure quality in care delivery as well as health reform initiatives to ensure adequacy of subsidies/tax credits to achieve affordable coverage for the under 65 population (including but not limited to HR 3200).

Monitor health reform legislation, provided strategic advice on issues related to pending health reform legislation including physician quality reporting requirements and palliative care.

Monitor health reform legislation, provided strategic advice on issues related to pending health reform legislation including physician quality reporting requirements and palliative care.

Provide background information regarding the political and policy status of health care reform, including the development and structuring of health reform initiatives and how they could impact the hospital sector (including but not limited to HR 3200).

Provide background information regarding the political and policy status of health care reform, including the development and structuring of health reform initiatives and how they could impact the hospital sector (including but not limited to HR 3200).

Advocate for cost containment initiatives such as comparative effectiveness research and patient safety (including but not limited to S. 3408); advocate for policies related to the development and utilization of a state and/or federal prescription drug formulary (including, but not limited to, HR 3200).

Advocate for policies related to the development of public standards for food ingredients and safety (including but not limited to S. 3385).

Advocate for policies related to the development of public standards for food ingredients and safety (including but not limited to S. 3385).

Advocate for initiatives designed to improve safety, enhance quality and constrain costs through generic utilization and pharmacy management techniques, as well as promote initiatives aimed at developing a policy to provide home delivery and counseling services for the chronically ill population; advocate for the creation of a workable, science-based regulatory pathway for access to affordable generic biologic medications a (including but not limited to H.R. 1427, S. 726, H.R. 1548).

Advocate for initiatives designed to improve safety, enhance quality and constrain costs through generic utilization and pharmacy management techniques, as well as promote initiatives aimed at developing a policy to provide home delivery and counseling services for the chronically ill population; advocate for the creation of a workable, science-based regulatory pathway for access to affordable generic biologic medications a (including but not limited to H.R. 1427, S. 726, H.R. 1548).

Advocate for cost containment policies related to comparative effectiveness, health information technology, and for policies on broader health care reform initiatives (including but not limited to S. 391). Advocate for cost containment policies related to the creation of a regulatory pathway for generic biologic medications (including but not limited to H.R. 1427, S. 726 and H.R. 1548).

Advocate for cost containment policies related to the creation of a regulatory pathway for generic biologic medications (including but not limited to H.R. 1427, S. 726 and H.R. 1548).

Advocate for biopharmaceutical cost containment policies aimed at creating a workable, science-based regulatory pathway for access to affordable generic biologic medications (including but not limited to H.R. 1427, S. 726 and H.R. 1548)

Advocate for biopharmaceutical cost containment policies aimed at creating a workable, science-based regulatory pathway for access to affordable generic biologic medications (including but not limited to H.R. 1427, S. 726 and H.R. 1548)

Advocate for the creation of a regulatory pathway for generic biologic medications and policies that promotes innovation and competition and ensures affordability in the pharmaceutical marketplace, including but not limited to H.R. 1427, S. 726 and H.R. 1548).

Advocate for the creation of a regulatory pathway for generic biologic medications and policies that promotes innovation and competition and ensures affordability in the pharmaceutical marketplace, including but not limited to H.R. 1427, S. 726 and H.R. 1548).

Advocate for policies designed to improve the long-term care delivery structure by providing home and community-based state options, addressing health care workforce shortages and ensuring quality in care delivery as well as health reform initiatives to ensure adequacy of subsidies/tax credits to achieve affordable coverage for the under 65 population.

Advocate for policies designed to improve the long-term care delivery structure by providing home and community-based state options, addressing health care workforce shortages and ensuring quality in care delivery as well as health reform initiatives to ensure adequacy of subsidies/tax credits to achieve affordable coverage for the under 65 population.

Advocate for cost containment policies, including generic access and the removal of barriers to greater competition in the pharmaceutical marketplace (including but not limited to H.R. 1427, S. 726 and H.R. 1548).

Average Manufacturers Price/AMP including H.R. 6331 Any matters relating to access to generic drugs

Advocate for cost containment policies, including generic access and the removal of barriers to greater competition in the pharmaceutical marketplace (including but not limited to H.R. 1427, S. 726 and H.R. 1548).

Advocate for cost containment policies related to comparative effectiveness, health information technology, and for policies on broader health care reform initiatives (including but not limited to S. 391).

Advocate for cost containment policies related to the creation of a regulatory pathway for generic biologic medications (including but not limited to H.R. 1427, S. 726 and H.R. 1548).

Advocate for cost containment policies related to comparative effectiveness, health information technology, and for policies on broader health care reform initiatives (including but not limited to S. 391). Advocate for cost containment policies related to the creation of a regulatory pathway for generic biologic medications (including but not limited to H.R. 1427, S. 726 and H.R. 1548).

Advocate for policies related to the development of public standards for food ingredients and safety (including but not limited to S. 3385).

Advocate for policies related to the development of public standards for food ingredients and safety (including but not limited to S. 3385).

Advocate for policies related to the development of public standards for food ingredients and safety (including but not limited to S. 3385).

Average Manufacturers Price/AMP including H.R. 6331 Any matters relating to access to generic drugs

Advocate for cost containment policies, including generic access and the removal of barriers to greater competition in the pharmaceutical marketplace (including but not limited to H.R. 1427, S. 726 and H.R. 1548).

Advocate for cost containment policies, including generic access and the removal of barriers to greater competition in the pharmaceutical marketplace (including but not limited to H.R. 1427, S. 726 and H.R. 1548).

Advocate for biopharmaceutical cost containment policies aimed at creating a workable, science-based regulatory pathway for access to affordable generic biologic medications (including but not limited to H.R. 1427, S. 726 and H.R. 1548)

Advocate for biopharmaceutical cost containment policies aimed at creating a workable, science-based regulatory pathway for access to affordable generic biologic medications (including but not limited to H.R. 1427, S. 726 and H.R. 1548)

Advocate for policies designed to improve the long-term care delivery structure by addressing health care workforce shortages and ensuring quality in care delivery as well as initiatives to ensure adequacy of subsidies/tax credits to achieve affordable coverage.

Advocate for policies designed to improve the long-term care delivery structure by addressing health care workforce shortages and ensuring quality in care delivery as well as initiatives to ensure adequacy of subsidies/tax credits to achieve affordable coverage.

Advocate for the creation of a regulatory pathway for generic biologic medications and policies that promotes innovation and competition and ensures affordability in the pharmaceutical marketplace, including but not limited to H.R. 1427, S. 726 and H.R. 1548).

Advocate for the creation of a regulatory pathway for generic biologic medications and policies that promotes innovation and competition and ensures affordability in the pharmaceutical marketplace, including but not limited to H.R. 1427, S. 726 and H.R. 1548).

Advocate for initiatives designed to improve safety, enhance quality and constrain costs through generic utilization and pharmacy management techniques, as well as promote initiatives aimed at developing a policy to provide home delivery and counseling services for the chronically ill population; advocate for the creation of a workable, science-based regulatory pathway for access to affordable generic biologic medications a (including but not limited to H.R. 1427, S. 726, H.R. 1548).

Advocate for initiatives designed to improve safety, enhance quality and constrain costs through generic utilization and pharmacy management techniques, as well as promote initiatives aimed at developing a policy to provide home delivery and counseling services for the chronically ill population; advocate for the creation of a workable, science-based regulatory pathway for access to affordable generic biologic medications a (including but not limited to H.R. 1427, S. 726, H.R. 1548).

NO LOBBYING ACTIVITY

Provide strategic assessment of environment for comprehensive delivery, coverage, and financing reforms; advocate for institution of quality/value incentives within the Medicare program

Provide strategic assessment of environment for comprehensive delivery, coverage, and financing reforms; advocate for institution of quality/value incentives within the Medicare program

Provide strategic assessment of environment for comprehensive delivery, coverage, and financing reforms; advocate for institution of quality/value incentives within the Medicare program

Provide strategic assessment of environment for comprehensive delivery, coverage, and financing reforms; advocate for institution of quality/value incentives within the Medicare program

Advocate for initiatives designed to improve safety, enhance quality, and constrain costs through the use of health information technology (including but not limited to H.R. 1)

Advocate for initiatives designed to improve safety, enhance quality, and constrain costs through the use of health information technology (including but not limited to H.R. 1)

Advocated for cost containment policies including generic access, health information technology, and comparative effectiveness research (including but not limited to H.R. 1427, S. 726, H.R. 1548, and H.R. 1) and policies that promote competition in the pharmaceutical marketplace.

Advocated for cost containment policies including generic access, health information technology, and comparative effectiveness research (including but not limited to H.R. 1427, S. 726, H.R. 1548, and H.R. 1) and policies that promote competition in the pharmaceutical marketplace.

Advocated for cost containment policies including generic access, health information technology, and comparative effectiveness research (including but not limited to H.R. 1427, S. 726, H.R. 1548, and H.R. 1) and policies that promote competition in the pharmaceutical marketplace.

Advocate for cost containment initiatives such as comparative effectiveness research and patient safety; advocate for policies related to the development of public standards for food ingredients and safety

Advocate for policies related to the development of public standards for food ingredients and safety

Advocate for policies related to the development of public standards for food ingredients and safety

Average Manufacturers Price/AMP including H.R. 6331 Any matters relating to access to generic drugs

Advocate for cost containment policies, including generic access and the removal of barriers to greater competition in the pharmaceutical marketplace (including but not limited to H.R. 1427, S. 726 and H.R. 1548)

Advocate for cost containment policies, including generic access and the removal of barriers to greater competition in the pharmaceutical marketplace (including but not limited to H.R. 1427, S. 726 and H.R. 1548)

Provide strategic assessment of environment for comprehensive delivery, coverage, and financing reforms; advocate for institution of quality/value incentives within the Medicare program

Provide strategic assessment of environment for comprehensive delivery, coverage, and financing reforms; advocate for institution of quality/value incentives within the Medicare program

NO LOBBYING ACTIVITY

Advocated for cost containment policies including generic access, health information technology, and comparative effectiveness research (including but not limited to H.R. 1427, S. 726, H.R. 1548, and H.R. 1) and policies that promote competition in the pharmaceutical marketplace.

Advocated for cost containment policies including generic access, health information technology, and comparative effectiveness research (including but not limited to H.R. 1427, S. 726, H.R. 1548, and H.R. 1) and policies that promote competition in the pharmaceutical marketplace.

Advocated for cost containment policies including generic access, health information technology, and comparative effectiveness research (including but not limited to H.R. 1427, S. 726, H.R. 1548, and H.R. 1) and policies that promote competition in the pharmaceutical marketplace.

Advocate for initiatives designed to improve safety, enhance quality and constrain costs through generic utilization and pharmacy management techniques, as well as promote initiatives aimed at developing a policy to provide home delivery and counseling services for the chronically ill population; advocate for the creation of a workable, science-based regulatory pathway for access to affordable generic biologic medications a (including but not limited to H.R. 1427, S. 726, H.R. 1548, and H.R. 1)

Advocate for initiatives designed to improve safety, enhance quality and constrain costs through generic utilization and pharmacy management techniques, as well as promote initiatives aimed at developing a policy to provide home delivery and counseling services for the chronically ill population; advocate for the creation of a workable, science-based regulatory pathway for access to affordable generic biologic medications a (including but not limited to H.R. 1427, S. 726, H.R. 1548, and H.R. 1)

Advocate for the creation of a regulatory pathway for generic biologic medications and policies that promote competition in the pharmaceutical marketplace, including but not limited to H.R. 1427, S. 726 and H.R. 1548).

Advocate for the creation of a regulatory pathway for generic biologic medications and policies that promote competition in the pharmaceutical marketplace, including but not limited to H.R. 1427, S. 726 and H.R. 1548).

Advocate for cost containment policies related to comparative effectiveness, health information technology, and for policies on broader health care reform initiatives (including but not limited to H.R. 1, S. 391). Advocate for cost containment policies related to the creation of a regulatory pathway for generic biologic medications (including but not limited to H.R. 1427, S. 726 and H.R. 1548).

Advocate for cost containment policies related to comparative effectiveness, health information technology, and for policies on broader health care reform initiatives (including but not limited to H.R. 1, S. 391).

Advocate for policies designed to improve the long-term care delivery structure by addressing health care workforce shortages and ensuring quality in care delivery as well as initiatives aimed at ensuring all Americans have affordable coverage

Advocate for policies designed to improve the long-term care delivery structure by addressing health care workforce shortages and ensuring quality in care delivery as well as initiatives aimed at ensuring all Americans have affordable coverage

Advocate for biopharmaceutical cost containment policies aimed at creating a workable, science-based regulatory pathway for access to affordable generic biologic medications (including but not limited to H.R. 1427, S. 726 and H.R. 1548)

Advocate for biopharmaceutical cost containment policies aimed at creating a workable, science-based regulatory pathway for access to affordable generic biologic medications (including but not limited to H.R. 1427, S. 726 and H.R. 1548)

Provide guidance and advocate for broad federal health care initiatives aimed at constraining costs, improving quality and value, and expanding coverage.

Provide guidance and advocate for broad federal health care initiatives aimed at constraining costs, improving quality and value, and expanding coverage.

Advocate for policies related to the development of public standards for food ingredients and safety

Advocate for policies related to the development of public standards for food ingredients and safety

Advocate for cost containment initiatives such as comparative effectiveness research and patient safety; advocate for policies related to the development of public standards for food ingredients and safety

Advocate for cost containment policies, including generic access and the removal of barriers to greater competition in the pharmaceutical marketplace (including but not limited to H.R. 1427, S. 726 and H.R. 1548)

Advocate for cost containment policies, including generic access and the removal of barriers to greater competition in the pharmaceutical marketplace (including but not limited to H.R. 1427, S. 726 and H.R. 1548)

Average Manufacturers Price/AMP including H.R. 6331 Any matters relating to access to generic drugs

NO LOBBYING ACTIVITY

NO LOBBYING ACTIVITY

Advocate for cost containment policies, including generic access and the removal of barriers to greater competition in the pharmaceutical marketplace (including but not limited to H.R. 1038, S. 623, H.R. 5629, H.R. 1956, S. 1505, S. 1695). Food and Drug Administration Amendents Act of 2007 (H.R. 3580) Counterfeit Drugs/Import safety/Pedigree Electronic prescribing (including H.R. 6331, S. 2408, and H.R. 4296) Prescription drug importation/re-importation Average Manufacturers Price/AMP

Advocate for cost containment policies, including generic access and the removal of barriers to greater competition in the pharmaceutical marketplace (including but not limited to H.R. 1038, S. 623, H.R. 5629, H.R. 1956, S. 1505, S. 1695). Food and Drug Administration Amendents Act of 2007 (H.R. 3580) Counterfeit Drugs/Import safety/Pedigree Electronic prescribing (including H.R. 6331, S. 2408, and H.R. 4296) Prescription drug importation/re-importation Average Manufacturers Price/AMP

-Advocated for cost containment policies including generic access, e-prescribing, and comparative effectiveness (including H.R. 1038 and S. 623) and policies that promote competition in the pharmaceutical marketplace (including but not limited to HR 5629, HR 1956, S 1505, and S. 1695).

-Advocated for cost containment policies including generic access, e-prescribing, and comparative effectiveness (including H.R. 1038 and S. 623) and policies that promote competition in the pharmaceutical marketplace (including but not limited to HR 5629, HR 1956, S 1505, and S. 1695).

-Advocated for cost containment policies including generic access, e-prescribing, and comparative effectiveness (including H.R. 1038 and S. 623) and policies that promote competition in the pharmaceutical marketplace (including but not limited to HR 5629, HR 1956, S 1505, and S. 1695).

Advocate for policies designed to improve the long-term care delivery structure by addressing health care workforce shortages and ensuring quality in care delivery (including but not limited to S. 799 and H.R. 1621) as well as initiatives aimed at ensuring all Americans have affordable coverage (including but not limited to S.334).

Advocate for policies designed to improve the long-term care delivery structure by addressing health care workforce shortages and ensuring quality in care delivery (including but not limited to S. 799 and H.R. 1621) as well as initiatives aimed at ensuring all Americans have affordable coverage (including but not limited to S.334).

Advocate for the creation of a regulatory pathway for generic biologic medications and policies that promote competition in the pharmaceutical marketplace, including but not limited to H.R. 1038, S. 623, H.R. 5629, H.R. 1956, S. 1505, S. 1695; advocate for cost containment policies related to electronic prescriptions including but not limited H.R. 6631, S. 2408, H.R. 4296.

Advocate for cost containment policies related to electronic prescriptions (including H.R. 6331, S. 2408, and H.R. 4296).

Advocate for the creation of a regulatory pathway for generic biologic medications and policies that promote competition in the pharmaceutical marketplace, including but not limited to H.R. 1038, S. 623, H.R. 5629, H.R. 1956, S. 1505, S. 1695; advocate for cost containment policies related to electronic prescriptions including but not limited H.R. 6631, S. 2408, H.R. 4296.

Advocate for biopharmaceutical cost containment policies aimed at creating a workable, science-based regulatory pathway for access to affordable generic biologic medications (including but not limited to H.R. 1038, S. 623, H.R. 5629)

Advocate for biopharmaceutical cost containment policies aimed at creating a workable, science-based regulatory pathway for access to affordable generic biologic medications (including but not limited to H.R. 1038, S. 623, H.R. 5629)

Advocate for cost containment policies related to electronic prescriptions, comparative effectiveness, and advocate for policies on broader health care reform initiatives (including but not limited to H.R. 6631, S. 2408, H.R. 4296, S. 334). Advocate for cost containment policies related to the creation of a regulatory pathway for generic biologic medications (including but not limited to H.R. 1038, S. 623, H.R. 5629, H.R. 1956, S. 1505, S. 1695).

-Advocate for cost containment policies related to the creation of a regulatory pathway for generic biologic medications (including but not limited to H.R. 1038, S. 623, H.R. 5629, H.R. 1956, S. 1505, S. 1695).

TERMINATION REPORT NO LOBBYING ACTIVITIES

Advocate for initiatives designed to improve safety, enhance quality and constrain costs through generic utilization and the use of electronic prescribing (including but not limited to H.R. 1038, S. 623, H.R. 5629, H.R. 1956, S. 1505, S. 1695, H.R. 6631, S. 2408, and H.R. 4296)

Advocate for initiatives designed to improve safety, enhance quality and constrain costs through generic utilization and the use of electronic prescribing (including but not limited to H.R. 1038, S. 623, H.R. 5629, H.R. 1956, S. 1505, S. 1695, H.R. 6631, S. 2408, and H.R. 4296)

Advocate for initiatives designed to improve safety, enhance quality and constrain costs through generic utilization and the use of electronic prescribing (including but not limited to H.R. 1038, S. 623, H.R. 5629, H.R. 1956, S. 1505, S. 1695, H.R. 6631, S. 2408, and H.R. 4296)

Advocate for policy initiatives to allow for the dissemination of Medicare data to improve quality and medical outcomes (including -- but not limited to -- S.3101 and H.R. 6331); advocate for cost containment policies related to comparative effectiveness research and patient safety (including but not limited to S. 3408); advocate for policies related to the development of public standards for food ingredients and safety (including but not limited to S. 3385).

Advocate for policies related to the development of public standards for food ingredients and safety (including but not limited to S. 3385).

Advocate for policies related to the development of public standards for food ingredients and safety (including but not limited to S. 3385).

Advocate for policy initiatives to allow for the dissemination of Medicare data to improve quality and medical outcomes (including -- but not limited to -- S.3101 and H.R. 6331); advocate for cost containment policies related to comparative effectiveness research and patient safety (including but not limited to S. 3408); advocate for policies related to the development of public standards for food ingredients and safety (including but not limited to S. 3385).

Advocate for initiatives designed to improve safety, enhance quality and constrain costs through generic utilization and the use of electronic prescribing (including -- but not limited to -- H.R. 1038, S. 623, H.R. 5629, H.R. 1956, S. 1505, S. 1695, H.R. 6331, S. 2408, and H.R. 4296).

Advocate for initiatives designed to improve safety, enhance quality and constrain costs through generic utilization and the use of electronic prescribing (including -- but not limited to -- H.R. 1038, S. 623, H.R. 5629, H.R. 1956, S. 1505, S. 1695, H.R. 6331, S. 2408, and H.R. 4296).

Advocating for reauthorization and expansion of programs to fund juvenile diabetes research, including the Special Type 1 Diabetes Program (including but not limited to H.R. 6331).

Advocate for cost containment policies related to electronic prescriptions, comparative effectiveness (H.R. 6631, S. 2408, H.R. 4296 and S.3385) Advocate for policies on broader health care reform initiatives (includingb ut not limited to H.R. 6331 and S. 334) Advocate for cost containment policies related to the creation of a regulatory pathway for generic biologic medications (including but not limited to H.R. 1038, S. 623, H.R. 5629, H.R. 1956, S. 1505, S. 1695).

-Advocate for cost containment policies related to electronic prescriptions (H.R. 6331, H.R. 4296 and S. 2408) -Advocate for policies related to broader health care reform initiatives (S. 334).

Advocate for biopharmaceutical cost containment policies aimed at creating a workable, science-based regulatory pathway for access to generic biologic medications (including but not limited to H.R. 1038, S. 623, H.R. 5629, H.R. 1956, S. 1505, S. 1695).

Advocate for biopharmaceutical cost containment policies aimed at creating a workable, science-based regulatory pathway for access to generic biologic medications (including but not limited to H.R. 1038, S. 623, H.R. 5629, H.R. 1956, S. 1505, S. 1695).

Advocate for cost containment policies related to electronic prescriptions (including H.R. 6331, S. 2408, and H.R. 4296).

Advocate for the creation of a regulatory pathway for generic biologic medications and policies that promote competition in the pharmaceutical marketplace (including but not limited to H.R. 1038, S. 623, H.R. 5629, H.R. 1956, S. 1505, S. 1695).; advocate for cost containment policies related to electronic prescriptions (including H.R. 6331, S. 2408, and H.R. 4296).

Advocate for the creation of a regulatory pathway for generic biologic medications and policies that promote competition in the pharmaceutical marketplace (including but not limited to H.R. 1038, S. 623, H.R. 5629, H.R. 1956, S. 1505, S. 1695).; advocate for cost containment policies related to electronic prescriptions (including H.R. 6331, S. 2408, and H.R. 4296).

Advocated for policies aimed at modifying the asset-transfer provisions of the Deficit Reduction Act of 2005 to ensure charitable donations and other similar expenditure do not inadvertently disqualify beneficiaries from Medicaid eligibility (including but not limited to H.R. 6331).

Advocated for policies aimed at modifying the asset-transfer provisions of the Deficit Reduction Act of 2005 to ensure charitable donations and other similar expenditure do not inadvertently disqualify beneficiaries from Medicaid eligibility (including -- but not limited to -- S. 3101 and H.R. 6331).

Advocate for policies designed to improve the long-term care delivery structure by addressing health care workforce shortages and ensuring quality in care delivery (including -- but not limited to -- S. 799 and H.R. 1621, and H.R. 6331), as well as initiatives aimed at expanding health coverage (including but not limited to S. 334).

Advocate for policies designed to improve the long-term care delivery structure by addressing health care workforce shortages and ensuring quality in care delivery (including -- but not limited to -- S. 799, H.R. 1621, and H.R. 6331), as well as initiatives aimed at expanding health coverage (including but not limited to S. 334).

-Advocated for policies promoting broad health coverage reform, including support for initiatives designed to reform retiree health liabilities that undermine competitiveness.-Advocated for cost containment policies including generic access and comparative effectiveness (including H.R. 1038 and S. 623) and policies that promote competition in the pharmaceutical marketplace (including but not limited to HR 5629, HR 1956, S 1505, and S. 1695).

-Advocated for cost containment policies including generic access and comparative effectiveness (including H.R. 1038 and S. 623) and policies that promote competition in the pharmaceutical marketplace (including but not limited to HR 5629, HR 1956, S 1505, and S. 1695).

Average Manufacturers Price/AMP including H.R. 6331 Any matters relating to access to generic drugs

Advocate for cost containment policies, including generic access and the removal of barriers to greater competition in the pharmaceutical marketplace (including but not limited to H.R. 1038, S. 623, H.R. 5629, H.R. 1956, S. 1505, S. 1695). Food and Drug Administration Amendents Act of 2007 (H.R. 3580) Citizens Petitions, including but not limited to S. 25 and S. 1080 Counterfeit Drugs/Import safety/Pedigree Electronic prescribing (including H.R. 6331, S. 2408, and H.R. 4296) Prescription drug importation/re-importation Average Manufacturers Price/AMP

Advocate for policy initiatives to allow for the dissemination of Medicare data to improve quality and medical outcomes (including -- but not limited to -- S.3101 and H.R. 6331); advocate for cost containment policies related to comparative effectiveness research and patient safety (including H.R. 3162); advocate for policies related to the development of public standards for food ingredients.

Advocate for policy initiatives to allow for the dissemination of Medicare data to improve quality and medical outcomes (including -- but not limited to -- S.3101 and H.R. 6331); advocate for cost containment policies related to comparative effectiveness research and patient safety (including H.R. 3162); advocate for policies related to the development of public standards for food ingredients.

Advocate for initiatives designed to improve safety, enhance quality and constrain costs through generic utilization and the use of electronic prescribing (including -- but not limited to -- S. 3101 and H.R. 6331).

Advocate for initiatives designed to improve safety, enhance quality and constrain costs through generic utilization and the use of electronic prescribing (including -- but not limited to -- S. 3101 and H.R. 6331).

Advocate for initiatives designed to improve safety, enhance quality and constrain costs through generic utilization and the use of electronic prescribing (including -- but not limited to -- S. 3101 and H.R. 6331).

Advocating for reauthorization and expansion of programs to fund juvenile diabetes research, including the Special Type 1 Diabetes Program (including -- but not limited to -- S. 3101 and H.R. 6331).

-Advocate for cost containment policies related to the creation of a regulatory pathway for generic biologic medications (S. 623 and H.R. 1038) -Advocate for cost containment policies related to electronic prescriptions and comparative effectiveness -Advocate for policies related to broader health care reform initiatives (S. 334).

-Advocate for cost containment policies related to the creation of a regulatory pathway for generic biologic medications (S. 623 and H.R. 1038) -Advocate for cost containment policies related to electronic prescriptions, comparative effectiveness, Medicare coverage of end-stage renal disease service; advocate for policies on broader health care reform initiatives (S. 334).

Advocate for biopharmaceutical cost containment policies aimed at creating a workable, science-based regulatory pathway for access to generic biologic medications (including -- but not limited to -- H.R. 1038, S. 623, H.R. 5629).

Advocate for biopharmaceutical cost containment policies aimed at creating a workable, science-based regulatory pathway for access to generic biologic medications (including -- but not limited to -- H.R. 1038, S. 623, H.R. 5629).

Advocate for the creation of a regulatory pathway for generic biologic medications and policies that promote competition in the pharmaceutical marketplace, including -- but not limited to -- S. 623, H.R. 1038, H.R. 5629; advocate for cost containment policies related to electronic prescriptions.

Advocate for the creation of a regulatory pathway for generic biologic medications and policies that promote competition in the pharmaceutical marketplace, including -- but not limited to -- S. 623, H.R. 1038, H.R. 5629; advocate for cost containment policies related to electronic prescriptions.

Advocated for policies aimed at modifying the asset-transfer provisions of the Deficit Reduction Act of 2005 to ensure charitable donations and other similar expenditure do not inadvertently disqualify beneficiaries from Medicaid eligibility (including -- but not limited to -- S. 3101 and H.R. 6331).

Advocated for policies aimed at modifying the asset-transfer provisions of the Deficit Reduction Act of 2005 to ensure charitable donations and other similar expenditure do not inadvertently disqualify beneficiaries from Medicaid eligibility (including -- but not limited to -- S. 3101 and H.R. 6331).

Advocate for policies designed to improve the long-term care delivery structure by addressing health care workforce shortages and ensuring quality in care delivery (including -- but not limited to -- S. 799 and H.R. 1621).

Advocate for policies designed to improve the long-term care delivery structure by addressing health care workforce shortages and ensuring quality in care delivery (including S. 799 and H.R. 1621).

Advocate for policies designed to improve the long-term care delivery structure by addressing health care workforce shortages and ensuring quality in care delivery (including -- but not limited to -- S. 799 and H.R. 1621).

-Advocated for cost containment policies including generic access and comparative effectiveness (including H.R. 1038 and S. 623) and policies that promote competition in the pharmaceutical marketplace -Advocated for policies promoting broad health coverage reform, including support for initiatives designed to reform retiree health liabilities that undermine competitiveness.

-Advocated for cost containment policies including generic access and comparative effectiveness (including H.R. 1038 and S. 623) and policies that promote competition in the pharmaceutical marketplace -Advocated for policies promoting broad health coverage reform, including support for initiatives designed to reform retiree health liabilities that undermine competitiveness.

Advocate for cost containment policies, including generic access and the removal of barriers to greater competition in the pharmaceutical marketplace, including Medicaid rebates.

Advocate for cost containment policies, including generic access and the removal of barriers to greater competition in the pharmaceutical marketplace (including -- but not limited to -- H.R. 1038, S. 623, H.R. 5629).

Advocate for cost containment policies, including generic access and the removal of barriers to greater competition in the pharmaceutical marketplace (including -- but not limited to -- H.R. 1038, S. 623, H.R. 5629).

Advocate for the creation of a regulatory pathway for generic biologic medications and policies that promote competition in the pharmaceutical marketplace, including S. 623, H.R. 1038, H.R. 5629; advocate for cost containment policies related to electronic prescriptions.

Advocate for the creation of a regulatory pathway for generic biologic medications and policies that promote competition in the pharmaceutical marketplace, including S. 623, H.R. 1038, H.R. 5629; advocate for cost containment policies related to electronic prescriptions.

Advocate for the creation of a regulatory pathway for generic biologic medications and policies that promote competition in the pharmaceutical marketplace, including S. 623, H.R. 1038, H.R. 5629; advocate for cost containment policies related to electronic prescriptions.

Advocate for policy initiatives to allow for the dissemination of Medicare data to improve quality and medical outcomes; advocate for cost containment policies related to comparative effectiveness research and patient safety (including H.R. 3162); advocate for policies related to the development of public standards for food ingredients.

Advocate for policy initiatives to allow for the dissemination of Medicare data to improve quality and medical outcomes; advocate for cost containment policies related to comparative effectiveness research and patient safety (including H.R. 3162); advocate for policies related to the development of public standards for food ingredients.

Advocate for initiatives designed to improve safety, enhance quality and constrain costs through generic utilization and the use of electronic prescribing.

Advocate for initiatives designed to improve safety, enhance quality and constrain costs through generic utilization and the use of electronic prescribing.

Advocate for initiatives designed to improve safety, enhance quality and constrain costs through generic utilization and the use of electronic prescribing.

Advocating for reauthorization and expansion of programs to fund juvenile diabetes research, including the Special Type 1 Diabetes Program.

-Advocate for cost containment policies related to the creation of a regulatory pathway for generic biologic medications (S. 623 and H.R. 1038) -Advocate for cost containment policies related to electronic prescriptions, comparative effectiveness, Medicare coverage of end-stage renal disease services; advocate for policies related to broader health care reform initiatives (S. 334).

-Advocate for cost containment policies related to the creation of a regulatory pathway for generic biologic medications (S. 623 and H.R. 1038) -Advocate for cost containment policies related to electronic prescriptions, comparative effectiveness, Medicare coverage of end-stage renal disease services; advocate for policies related to broader health care reform initiatives (S. 334).

Advocate for biopharmaceutical cost containment policies aimed at creating a workable, science-based regulatory pathway for access to generic biologic medications (H.R. 1038, S. 623, H.R. 5629)

Advocate for biopharmaceutical cost containment policies aimed at creating a workable, science-based regulatory pathway for access to generic biologic medications (H.R. 1038, S. 623, H.R. 5629)

Advocated for policies aimed at modifying the asset-transfer provisions of the Deficit Reduction Act of 2005 to ensure charitable donations and other similar expenditure do not inadvertently disqualify beneficiaries from Medicaid eligibility.

Advocated for policies aimed at modifying the asset-transfer provisions of the Deficit Reduction Act of 2005 to ensure charitable donations and other similar expenditure do not inadvertently disqualify beneficiaries from Medicaid eligibility.

Advocate for policies designed to improve the long-term care delivery structure by addressing health care workforce shortages and ensuring quality in care delivery (including S. 799 and H.R. 1621).

Advocate for policies designed to improve the long-term care delivery structure by addressing health care workforce shortages and ensuring quality in care delivery (including S. 799 and H.R. 1621).

Advocate for policies designed to improve the long-term care delivery structure by addressing health care workforce shortages and ensuring quality in care delivery (including S. 799 and H.R. 1621).

Advocate for cost containment policies, including generic access and the removal of barriers to greater competition in the pharmaceutical marketplace (including H.R. 1038, S. 623, H.R. 5629).

Advocate for cost containment policies, including generic access and the removal of barriers to greater competition in the pharmaceutical marketplace (including H.R. 1038, S. 623, H.R. 5629).

Advocate for cost containment policies, including generic access and the removal of barriers to greater competition in the pharmaceutical marketplace (including H.R. 1038, S. 623, H.R. 5629).

-Advocated for cost containment policies including generic access and comparative effectiveness (including H.R. 1038 and S. 623) and policies that promote competition in the pharmaceutical marketplace -Advocated for policies promoting broad health coverage reform, including support for initiatives designed to reform retiree health liabilities that undermine competitiveness and policies related to Medicare coverage of end-stage renal disease services

-Advocated for cost containment policies including generic access and comparative effectiveness (including H.R. 1038 and S. 623) and policies that promote competition in the pharmaceutical marketplace -Advocated for policies promoting broad health coverage reform, including support for initiatives designed to reform retiree health liabilities that undermine competitiveness and policies related to Medicare coverage of end-stage renal disease services

Advocate for initiatives designed to improve safety, enhance quality, and constrain costs through the use of health information technology (including but not limited to H.R. 6331).

Advocate for initiatives designed to improve safety, enhance quality, and constrain costs through the use of health information technology (including but not limited to H.R. 6331).

Advocate for initiatives designed to improve safety, enhance quality, and constrain costs through the use of health information technology.

Advocate for initiatives designed to improve safety, enhance quality, and constrain costs through the use of health information technology.

Advocate for initiatives designed to improve safety, enhance quality, and constrain costs through the use of health information technology.

Advocate for initiatives designed to improve safety, enhance quality, and constrain costs through the use of health information technology (including but not limited to H.R. 6331).

Advocate for initiatives designed to improve safety, enhance quality, and constrain costs through the use of health information technology (including but not limited to H.R. 6331).

Advocate for policy initiatives to allow for the dissemination of Medicare data to improve quality and medical outcomes; Advocate for cost containment policies related to comparative effectiveness research and patient safety (including H.R. 3162).

Advocate for policy initiatives to allow for the dissemination of Medicare data to improve quality and medical outcomes; Advocate for cost containment policies related to comparative effectiveness research and patient safety (including H.R. 3162).

Advocate for policy initiatives to allow for the dissemination of Medicare data to improve quality and medical outcomes; Advocate for cost containment policies related to comparative effectiveness research and patient safety (including H.R. 3162).

Advocate for initiatives designed to improve safety, enhance quality, and constrain costs through the use of health information technology.

Advocate for initiatives designed to improve safety, enhance quality, and constrain costs through the use of health information technology.

Advocate for initiatives designed to improve safety, enhance quality, and constrain costs through the use of health information technology.

Advocate for biopharmaceutical cost-containment policies aimed at creating an abbreviated pathway for access to generic biologic medications (including H.R. 1038 and S. 623).

Advocate for biopharmaceutical cost-containment policies aimed at creating an abbreviated pathway for access to generic biologic medications (including H.R. 1038 and S. 623).

Advocate for the creation of a regulatory pathway for generic biologic medications and policies that promote competition in the pharmaceutical marketplace, including S. 623 and H.R. 1038.

Advocate for the creation of a regulatory pathway for generic biologic medications and policies that promote competition in the pharmaceutical marketplace, including S. 623 and H.R. 1038.

Advocated for policies aimed at modifying the asset-transfer provisions of the Deficit Reduction Act of 2005 to ensure charitable donations and other similar expenditure do not inadvertently disqualify beneficiaries from Medicaid eligibility.

Advocated for policies aimed at modifying the asset-transfer provisions of the Deficit Reduction Act of 2005 to ensure charitable donations and other similar expenditure do not inadvertently disqualify beneficiaries from Medicaid eligibility.

Advocate for policies designed to improve the long-term care delivery structure by addressing health care workforce shortages and ensuring quality in care delivery (including S. 799 and H.R. 1621)

Advocate for policies designed to improve the long-term care delivery structure by addressing health care workforce shortages and ensuring quality in care delivery (including S. 799 and H.R. 1621)

Advocate for policies designed to improve the long-term care delivery structure by addressing health care workforce shortages and ensuring quality in care delivery (including S. 799 and H.R. 1621)